We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$17.7M
Cap. Flow
+$78.3M
Cap. Flow %
7.08%
Top 10 Hldgs %
56.11%
Holding
90
New
21
Increased
23
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
PFE icon
Pfizer
PFE
+$15.7M
3
UTHR icon
United Therapeutics
UTHR
+$15.6M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.3M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$22.8M
2
NVO
Novo Nordisk
NVO
+$16.5M
3
HRTX icon
Heron Therapeutics
HRTX
+$9.45M
4
INCY icon
Incyte
INCY
+$5.91M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Miscellaneous 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HALO icon
26
Halozyme
HALO
$12.2B
$9.87M 0.89%
636,167
-54,032
-8% -$890K
TGTX icon
27
TG Therapeutics
TGTX
$8.37B
$9.73M 0.88%
1,733,628
+472,244
+37% +$3.29M
PTCT icon
28
PTC Therapeutics
PTCT
$5.64B
$9.71M 0.88%
287,245
-81,658
-22% -$3.55M
CHMA
29
DELISTED
Chiasma, Inc. Common Stock
CHMA
$8.07M 0.73%
1,630,221
– –
SRPT icon
30
Sarepta Therapeutics
SRPT
$2.33B
$8.02M 0.72%
+106,414
New +$12.6M
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$6.13B
$7.85M 0.71%
922,700
– –
MGNX icon
32
MacroGenics
MGNX
$262M
$7.42M 0.67%
581,554
+31,111
+6% +$448K
AIMT
33
DELISTED
Aimmune Therapeutics
AIMT
$7.26M 0.66%
+346,770
New +$7.08M
ETTX
34
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$7.03M 0.64%
1,180,178
– –
KDMN
35
DELISTED
Kadmon Holdings, Inc.
KDMN
$6.58M 0.59%
2,609,758
+405,556
+18% +$1.01M
DERM
36
DELISTED
Dermira, Inc.
DERM
$6.33M 0.57%
990,168
+330,286
+50% +$2.76M
ONC
37
CALL
BeOne Medicines Ltd
ONC
$39.7B
$6.12M 0.55%
+50,000
New +$6.64M
MYOK
38
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.94M 0.54%
+113,926
New +$6.06M
FATE icon
39
Fate Therapeutics
FATE
$292M
$5.93M 0.54%
+381,600
New +$7.31M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$5.8M 0.52%
722,974
+139,665
+24% +$1.52M
BMRN icon
41
BioMarin Pharmaceuticals
BMRN
$12.5B
$5.72M 0.52%
84,896
– –
DRNA
42
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.92M 0.45%
+342,755
New +$4.9M
AKBA icon
43
Akebia Therapeutics
AKBA
$264M
$4.81M 0.44%
1,227,191
+378,835
+45% +$1.62M
ZYME icon
44
Zymeworks
ZYME
$1.94B
$4.67M 0.42%
188,438
+381
+0.2% +$9.55K
XBIT icon
45
XBiotech
XBIT
$66.5M
$3.75M 0.34%
358,663
+26,852
+8% +$219K
FOMX
46
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.65M 0.33%
1,199,254
+83,444
+7% +$235K
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$3.44M 0.31%
1,437,965
+100,397
+8% +$239K
ORTX
48
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.37M 0.3%
28,341
-8,206
-22% -$1.15M
FTSV
49
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$3.33M 0.3%
519,298
+400,495
+337% +$3.29M
HRTX icon
50
CALL
Heron Therapeutics
HRTX
$63.2M
$3.28M 0.3%
+177,200
New +$3.26M
1
2
3 4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q3 2019 Portfolio in Review

As of Q3 2019, Sofinnova Investments held 90 positions worth $1.11B, up 1.6% from $1.09B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sofinnova Investments deployed $78.3M of net new capital in Q3 2019, opening 21 new positions and adding to 23 existing holdings. Its largest new stake was Amgen: 92,300 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Principia Biopharma Inc. Common Stock, an estimated $22.8M trimmed.

  • Sofinnova Investments's largest Q3 2019 buy was Amgen: 92,300 shares worth $17.9M.
  • Sofinnova Investments added most to Bristol-Myers Squibb in Q3 2019, an estimated $14.3M increase.
  • Sofinnova Investments's biggest Q3 2019 reduction was Principia Biopharma Inc. Common Stock, cutting an estimated $22.8M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2019, selling an estimated $16.5M.
  • Sofinnova Investments's ten largest holdings make up 56% of its $1.11B portfolio in Q3 2019.
  • Sofinnova Investments opened 21 new positions and closed 19 in Q3 2019.
  • Sofinnova Investments's portfolio value rose 1.6% quarter-over-quarter to $1.11B.

Based on Sofinnova Investments's 13F filing for Q3 2019, filed 14 Nov 2019.